Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

January 31, 2011

Conditions
Carcinoid Syndrome
Interventions
DRUG

BIM 23A760

BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.

Trial Locations (54)

2650

UZ Antwerpen, Edegem

3000

UZ GAsthuisberg, Leuven

3015

Erasmus MC, Rotterdam

9000

UZ Gent, Ghent

9700

UMCG, Groningen

13009

Institut Paoli Calmette, Marseille

13353

Charite Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin

16132

Ospedale San Martino, Genova

26100

Istituti Ospitalieri di Cremona, Cremona

28034

Hospital Universitario Ramon y Cajal, Madrid

28041

Hospital 12 de Octubre, Madrid

40138

Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna

41124

AO Universitaria Policlinico di Modena, Modena

44805

Centre René Gauducheau, Nantes

49100

Rabin Medical Center, Petah Tikva

55131

Universitätsmedizin Mainz, Mainz

69120

Universitätsklinikum Heidelberg, Heidelberg

83092

Donetsk National Medical University named after M. Gorkiy, Donetsk Regional Antitumor Center, Donetsk

83310

Narodny onkologicky ustav, Bratislava

88000

Uzhgorod national university, Postgraduate faculty, Uzhgorod Central City Clinical Hospital, Uzhhorod

91120

Hadassah Medical Organization, Jerusalem

125367

"Non-state Institution of Public health Central Clinical hospital # 1, public corporation Russian railways", Moscow

197089

St-Petersburg State Medical University named after academician Pavlov I.P., Saint Petersburg

198255

St-Petersburg State Institution of Public Health City Clinical Oncology dispensary, Saint Petersburg

300053

Tula Regional Oncology Dispensary, Tula

394000

Voronezh Regional Clinical Oncology Dispensary, Voronezh

420111

Republican Clinical Oncology dispensary of the Ministry of Health of Republic of Tatarstan, Kazan'

656052

Altay Regional Oncology dispensary, Barnaul

A-9010

University Hospital, Internal Medicine - Oncology, Vienna

500 05

Fakultní nemocnice Hradec Králové, Hradec Králové

775 20

Fakultní nemocnice Olomouc, Olomouc

180 81

Fakultní nemocnice Na Bulovce, Ústav radiační onkologie, Prague

FIN-00029

Helsinki Central University Hospital, Helsinki

FIN-20521

Turku University Hospital, Turku

Unknown

Service de Gastroentérologie, Clichy

Unité de Gastro-Entérologie, Villejuif

St James's Hospital, Dublin

Cedex 03

Unité d'Oncologie Médicale, Lyon

06132

Ospedale S.Maria della Misericordia, Perugia

00109

"Università degli Studi di Roma La Sapienza, II Facoltà di Medicina e Chirurgia, Ospedale Sant'Andrea", Roma

LV-1079

Latvian Oncology centre of Riga Eastern Clinical University Hospital, Riga

LV-4201

Vidzemes Hospital, Valmiera

44-101

Centrum Onkologii Instytut im.M. Sklodowskiej-Curie oddzial w Gliwicach, Gliwice

, 31-501

Szpital Uniwersytecki w Krakowie, Krakow

02-785

Instytut im Marii Sklodowskiej Curie, Warsaw

50-367

Samodzielny Publiczny Szpital Kliniczny nr 1, Wroclaw, 50-367

03601

Martinska fakultna nemocnice, Martin

07014

Hospital Universitario Son Dureta, Palma de Mallorca

751 85

Akademiska Hospital, Dept of Oncology & Endocrinology, Uppsala

L9 7AL

University Hospital Aintree, Liverpool

EC1A 7BE

St Bartholomew's Hospital, London

NW3 2QG

Royal Free Hospital, London

M20 4BX

Christie Hospital and Holt Radium Institute, Manchester

PR2 9HT

Royal Preston Hospital, Sharoe Green Lane, Lancashire, Preston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY